Clinical Trials
35 trialsCyto-KIK
Columbia University
CANIQOL
Centre Francois Baclesse
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Emory University
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
SAMURAI
NRG Oncology
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Memorial Sloan Kettering Cancer Center
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Vanderbilt-Ingram Cancer Center
ZEBRA
Istituto Oncologico Veneto IRCCS
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
City of Hope Medical Center
SKIPPY 2
Leiden University Medical Center
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Dana-Farber Cancer Institute
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
M.D. Anderson Cancer Center
International Multicentric Study ARON-1
Hospital of Macerata
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
University of Texas Southwestern Medical Center
CABOLD
Gustave Roussy, Cancer Campus, Grand Paris
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
M.D. Anderson Cancer Center
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
UNICAB
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
CABRAMET
Centre Leon Berard
Autologous Dendritic Cell Vaccine in Kidney Cancer
University of Pittsburgh
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
University of Colorado, Denver
CARE1
Gustave Roussy, Cancer Campus, Grand Paris
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
Icahn School of Medicine at Mount Sinai
CABOGEN
Gruppo Oncologico Italiano di Ricerca Clinica
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
University of Utah
CABOMAYOR
Spanish Oncology Genito-Urinary Group
SRWEC
Spanish Oncology Genito-Urinary Group
BONSAI
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
BREAKPOINT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma
Asan Medical Center